+ All Categories
Home > Health & Medicine > Case Study - Breakthrough Treatment for HPV and Cervical Pre-Cancer

Case Study - Breakthrough Treatment for HPV and Cervical Pre-Cancer

Date post: 21-Dec-2014
Category:
Upload: sagentia
View: 234 times
Download: 1 times
Share this document with a friend
Description:
Breakthrough light activated drug device investigated for treatment of HPV and cervical pre-cancer. http://www.sagentia.com/photocure-hpv-device
1
The approach This is the first therapeutic treatment that uses advanced LED technology in a self-powered, disposable device which can be deployed inside a body cavity. The device contains a LED light source that in combination with a medicinal product initiates a photochemical reaction in exposed tissue. The end result “This is the first ever non-surgical treatment for HPV and precancerous lesions of the cervix to be successfully developed. If this sophisticated and breakthrough device is accepted, it will make way for a new era in cervical cancer treatment that will not only minimise patient risk and suffering but could also help reduce the burden of HPV on healthcare systems.” Dr. Peter Hillemanns, Professor and Chairman at the Department of Obstetrics and Photocure Breakthrough light activated drug device investigated for treatment of HPV and cervical pre-cancer
Transcript
Page 1: Case Study - Breakthrough Treatment for HPV and Cervical Pre-Cancer

The approach

This is the first therapeutic treatment that uses advanced LED

technology in a self-powered, disposable device which can be

deployed inside a body cavity. The device contains a LED light

source that in combination with a medicinal product initiates a

photochemical reaction in exposed tissue.

The end result

“This is the first ever non-surgical treatment for HPV and

precancerous lesions of the cervix to be successfully

developed. If this sophisticated and breakthrough device is

accepted, it will make way for a new era in cervical cancer

treatment that will not only minimise patient risk and suffering

but could also help reduce the burden of HPV on healthcare

systems.”Dr. Peter Hillemanns, Professor and Chairman at the Department of Obstetrics and Gynecology of Medical University Hannover andPrincipal investigator for the trial

PhotocureBreakthrough light activated drug device investigated for treatment of HPV and cervical pre-cancer

Recommended